CNTN
Tharimmune, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.28
+1.33%Margins
Gross margin
100.0%
EBITDA margin
-5860.7%
EBIT margin
-3595.2%
Net margin
-6559.3%
FCF margin
-1482.1%
-21.6%
Return on equity
-17.4%
Return on assets
-11.8%
Return on invested capital
0.00x
Asset turnover
-$22.2M
Cash from operations
$0.47
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026